Clinical Trials Study
Copyright ©The Author(s) 2022.
World J Clin Cases. Nov 6, 2022; 10(31): 11391-11402
Published online Nov 6, 2022. doi: 10.12998/wjcc.v10.i31.11391
Table 2 Baseline clinical characteristics of all patients
Characteristic
Control group (n = 38)
TCM group (n = 40)
P value
Age (yr)11.07 ± 2.2811.51 ± 2.770.338
Female sex, n (%)25 (65.8)28 (70)0.690
Weight (kg)39.18 ± 11.5541.61 ± 15.550.582
Duration of SLE (years)0.65 ± 1.370.78 ± 1.210.607
Duration of LN (years)0.15 ± 0.410.17 ± 0.280.559
Serum creatinine (μmol/L)61.73 ± 46.6851.46 ± 22.520.127
White blood cell count5.03 ± 3.225.83 ± 3.200.201
NE (%)53.85 ± 19.5457.56 ± 15.330.489
HGB (g/L)100.18 ± 16.93105.85 ± 23.730.308
PT (s)10.45 ± 0.9311.23 ± 2.090.115
APTT (s)35.48 ± 17.2537.6 ± 16.170.577
D-D (mg/L)1.08 ± 1.641.02 ± 1.320.161
Serum albumin (g/L)29.23 ± 5.9930.92 ± 4.610.167
Urine protein (g/24 h)1.29 ± 1.811.32 ± 1.110.314
Urine RBC count/HPF26.17 ± 37.9225.65 ± 37.590.24
Serum C3 (g/L)0.28 ± 0.180.39 ± 0.280.101
Serum C4 (g/L)0.05 ± 0.040.06 ± 0.050.782
BUN (IU/mL)6.94 ± 3.895.72 ± 2.310.057
ALT (mmol/L)33.20 ± 28.0432.88 ± 36.340.730
AST (mmol/L)40.00 ± 41.2139.61 ± 43.370.957
SLEDAI15.57 ± 5.0114.07 ± 3.490.315
ds-DNA postive, n (%)28 (73.6)33 (82.5)0.345